Report of Foreign Issuer (6-k)
11 4월 2014 - 5:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the
month of April 2014
Commission
File Number: 000-28508
Flamel Technologies, S.A.
(Translation
of registrant’s name into English)
Parc Club du Moulin à Vent
33 avenue du Dr. Georges Levy
69693 Vénissieux Cedex France
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Indicate by check mark whether registrant by furnishing the
information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
Yes
¨
No
x
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-____________
In March and April 2014, Flamel Technologies issued the press
releases attached hereto as Exhibit 99.1 and 99.2 and incorporated herein by reference.
EXHIBIT LIST
Exhibit
Number
|
|
Description
|
99.1
|
|
Press release announcing fourth quarter and full year 2013 results
|
99.2
|
|
Press release announcing positive results of a First-in-Man Clinical Trial with Micropump® Sodium Oxybate
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: April 10, 2014
|
Flamel Technologies, S.A.
|
|
|
|
By:
|
/s/ Michael S. Anderson
|
|
|
Name: Michael S. Anderson
|
|
|
Title: Chief Executive Officer
|
EXHIBIT INDEX
Exhibit
Number
|
|
Description
|
99.1
|
|
Press release announcing fourth quarter and full year 2013 results
|
99.2
|
|
Press release announcing positive results of a First-in-Man Clinical Trial with Micropump® Sodium Oxybate
|
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024